BIOMAT Database Logo BIOMAT Database Logo

Prognostic Factors for Advanced/Recurrent Breast Cancer Treated With Immune-cell Therapy. 2021

Rishu Takimoto, and Takashi Kamigaki, and Sachiko Okada, and Hiroshi Ibe, and Eri Oguma, and Shigenori Goto
Seta Clinic Group, Tokyo, Japan takimoto@j-immunother.com.

OBJECTIVE Advanced/recurrent breast cancer (ARBC) still has a poor prognosis; therefore, new treatment strategies are required. In this retrospective study, we aimed to investigate the efficacy of immune-cell therapy using T lymphocytes activated in vitro with or without dendritic cell vaccination in combination with standard therapies in terms of the survival of patients with ARBC. METHODS A total of 127 patients with ARBC were enrolled in this study. The correlation between overall survival and various clinical factors of each ARBC subset was examined by univariate and multivariate analyses. RESULTS Multivariate analysis demonstrated that performance status (PS) 0, the absence of prior chemotherapy, liver/pleural metastasis, and the presence of combined surgery in ARBC and PS 0 or the absence of liver metastasis in the HR+/HER- subset are indications for immune-cell therapy. CONCLUSIONS A survival benefit could be potentially obtained by a combination of immune-cell therapy with other therapies in ARBC patients.

UI MeSH Term Description Entries
D007167 Immunotherapy Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection. Immunotherapies
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009364 Neoplasm Recurrence, Local The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site. Local Neoplasm Recurrence,Local Neoplasm Recurrences,Locoregional Neoplasm Recurrence,Neoplasm Recurrence, Locoregional,Neoplasm Recurrences, Local,Recurrence, Local Neoplasm,Recurrence, Locoregional Neoplasm,Recurrences, Local Neoplasm,Locoregional Neoplasm Recurrences,Neoplasm Recurrences, Locoregional,Recurrences, Locoregional Neoplasm
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D003713 Dendritic Cells Specialized cells of the hematopoietic system that have branch-like extensions. They are found throughout the lymphatic system, and in non-lymphoid tissues such as SKIN and the epithelia of the intestinal, respiratory, and reproductive tracts. They trap and process ANTIGENS, and present them to T-CELLS, thereby stimulating CELL-MEDIATED IMMUNITY. They are different from the non-hematopoietic FOLLICULAR DENDRITIC CELLS, which have a similar morphology and immune system function, but with respect to humoral immunity (ANTIBODY PRODUCTION). Dendritic Cells, Interdigitating,Interdigitating Cells,Plasmacytoid Dendritic Cells,Veiled Cells,Dendritic Cells, Interstitial,Dendritic Cells, Plasmacytoid,Interdigitating Dendritic Cells,Interstitial Dendritic Cells,Cell, Dendritic,Cell, Interdigitating,Cell, Interdigitating Dendritic,Cell, Interstitial Dendritic,Cell, Plasmacytoid Dendritic,Cell, Veiled,Cells, Dendritic,Cells, Interdigitating,Cells, Interdigitating Dendritic,Cells, Interstitial Dendritic,Cells, Plasmacytoid Dendritic,Cells, Veiled,Dendritic Cell,Dendritic Cell, Interdigitating,Dendritic Cell, Interstitial,Dendritic Cell, Plasmacytoid,Interdigitating Cell,Interdigitating Dendritic Cell,Interstitial Dendritic Cell,Plasmacytoid Dendritic Cell,Veiled Cell
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

Rishu Takimoto, and Takashi Kamigaki, and Sachiko Okada, and Hiroshi Ibe, and Eri Oguma, and Shigenori Goto
Evaluation of prognostic factors for 233 patients with recurrent advanced breast cancer.
October 1991, Japanese journal of clinical oncology,
Rishu Takimoto, and Takashi Kamigaki, and Sachiko Okada, and Hiroshi Ibe, and Eri Oguma, and Shigenori Goto
Outcomes and Prognostic Factors for Locally Recurrent Rectal Cancer Treated With Proton Beam Therapy.
January 2023, Advances in radiation oncology,
Rishu Takimoto, and Takashi Kamigaki, and Sachiko Okada, and Hiroshi Ibe, and Eri Oguma, and Shigenori Goto
Inflammatory prognostic factors in advanced or recurrent esophageal squamous cell carcinoma treated with nivolumab.
February 2023, Cancer immunology, immunotherapy : CII,
Rishu Takimoto, and Takashi Kamigaki, and Sachiko Okada, and Hiroshi Ibe, and Eri Oguma, and Shigenori Goto
Exploratory predictive and prognostic factors in advanced breast cancer treated with metronomic chemotherapy.
March 2012, Anti-cancer drugs,
Rishu Takimoto, and Takashi Kamigaki, and Sachiko Okada, and Hiroshi Ibe, and Eri Oguma, and Shigenori Goto
Prognostic factors of advanced or postoperative recurrent non-small cell lung cancer targeted with immune check point inhibitors.
April 2019, Journal of thoracic disease,
Rishu Takimoto, and Takashi Kamigaki, and Sachiko Okada, and Hiroshi Ibe, and Eri Oguma, and Shigenori Goto
Prognostic factors in advanced metastatic and recurrent melanoma treated with DTIC.
February 1987, Tumori,
Rishu Takimoto, and Takashi Kamigaki, and Sachiko Okada, and Hiroshi Ibe, and Eri Oguma, and Shigenori Goto
Radiation therapy for locally advanced breast cancer: prognostic factors and complication rate.
October 1990, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology,
Rishu Takimoto, and Takashi Kamigaki, and Sachiko Okada, and Hiroshi Ibe, and Eri Oguma, and Shigenori Goto
[Endocrine therapy for advanced or recurrent breast cancer].
July 2001, Gan to kagaku ryoho. Cancer & chemotherapy,
Rishu Takimoto, and Takashi Kamigaki, and Sachiko Okada, and Hiroshi Ibe, and Eri Oguma, and Shigenori Goto
[Pharyngolaryngectomy for advanced and recurrent cancer: prognostic factors and complications].
January 2004, Revue de laryngologie - otologie - rhinologie,
Rishu Takimoto, and Takashi Kamigaki, and Sachiko Okada, and Hiroshi Ibe, and Eri Oguma, and Shigenori Goto
Lung Immune Therapy Evaluation (LITE) Risk, a Novel Prognostic Model for Patients With Advanced Non-Small Cell Lung Cancer Treated With Immune Checkpoint Blockade.
May 2023, Clinical lung cancer,
Copied contents to your clipboard!